Effects of cromakalim and glibenclamide in ischemic and reperfused hearts.
Tosaki
A
A
University of Connecticut Health Center, School of Medicine, Farmington 06030-1110, USA.
Engelman
R M
RM
Das
D K
DK
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001578:Benzopyrans / Q000494:pharmacology* / Q000627:therapeutic use; D019806:Cromakalim; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D005905:Glyburide / Q000494:pharmacology* / Q000627:therapeutic use; D066298:In Vitro Techniques; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000503:physiopathology*; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy / Q000503:physiopathology*; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley
D000889:Anti-Arrhythmia Agents; D001578:Benzopyrans; D011758:Pyrroles; D019806:Cromakalim; D005905:Glyburide